Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

There have been great strides in MASH (formerly kn

Message Board Public Reply | Private Reply | Keep | Replies (2)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154900
(Total Views: 603)
Posted On: 11/23/2023 12:37:32 PM
Avatar
Posted By: Drano
Re: Hulk767 #139246
There have been great strides in MASH (formerly known as NASH) drugs in the past year. There are at least 2 drugs that are close to approval.

Clinical trials for this disease are horribly expensive, requiring imaging and biopsies. Not only does a company have to pay these expenses, but they also have to pay the PATIENTS to do all of these procedures. If you haven't participated in clinical trials, as I have, you may be surprised to find out how lucrative they can be. I was just contacted to be paid $1300 just for getting a combo flu/COVID shot, which involved getting the shot and coming in again a couple times over the next 6 months to let them take some blood to measure antibody levels. Alas, I've already had my NOVAVAX Covid booster (which I highly recommend -- almost no side effects, and a better, non-mRNA, longer-lasting vaccine).

So if they want to pay me $1300 for getting a shot and a couple of blood draws, imagine what they'd have to pay a patient undergoing multiple biopsies that do nothing for their own condition, but are done in the name of science?

I always thought that Cyrus was WRONG to identify MASH/NASH/mishmash as the target. Too much competition, too expensive. Whereas HIV has a huge unmet need, and Leronlimab has a track record despite Amarex's best efforts to screw it up.

So, I am really happy that Dr. Lalezari seems to be taking the company in the right direction. By "right" I mean the direction that agrees with my preconceived notion.


(12)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us